Drug intelligence / Profile preview

HLX10 + oxaliplatin + tegafur + gimeracil + oteracil potassium

Development stage: Unknown
Lead developer: Henlius
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

HLX10 + oxaliplatin + tegafur + gimeracil + oteracil potassium is an investigational combination therapy for cancer, specifically studied in the neoadjuvant and adjuvant setting for gastric cancer. HLX10 is a fully humanized monoclonal antibody targeting the PD-1 receptor, functioning as an immune checkpoint inhibitor, while oxaliplatin is a platinum-based antineoplastic chemotherapy. Tegafur, gimeracil, and oteracil potassium together constitute S-1, an oral fluoropyrimidine derivative regimen used as chemotherapy: tegafur acts as a prodrug of 5-fluorouracil (5-FU), gimeracil inhibits 5-FU degradation, and oteracil reduces gastrointestinal toxicity. The combination aims to leverage both immunotherapy and cytotoxic chemotherapy to enhance antitumor activity, particularly for resectable gastric cancer[1][3]. HLX10 is developed by Henlius, and the combination is under investigation in phase III clinical trials for gastric cancer.

Other names: HLX10 + SOXHLX10 + S-1 + oxaliplatin

Targets

PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNAOPRT (Orotidine 5'-phosphate decarboxylase)DPYD (Dihydropyrimidine dehydrogenase)

Beyond the preview

Go deeper on HLX10 + oxaliplatin + tegafur + gimeracil + oteracil potassium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLX10 + oxaliplatin + tegafur + gimeracil + oteracil potassium.

Explore the full profile